AHA Scientific Sessions 2025 Abstract
Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups
Trial in peopleInterventions
Papers by Lily Kagan Stern
1 result